Changes to This Summary (04/04/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that mucosa-associated lymphoid tissue (MALT) lymphomas observed in pediatric patients usually present as low-stage disease, and pediatric gastric MALT lymphomas are associated with Helicobacter pylori and require no more than local therapy involving curative surgery and/or radiation therapy. Also added text to state that conjunctival MALT lymphomas are often associated with chlamydial psittaci infections (cited Stefanovic et al. as reference 54).
Added text to state that an oral retinoid (bexarotene) has been reported to be active against subcutaneous panniculitis-like T-cell lymphomas and cutaneous gamma-delta T-cell lymphomas in a series of 15 patients from three institutions (cited Mehta et al. as reference 67).
Added Nakatani et al. as reference 25.
Revised text to state that with the use of an acute lymphoblastic leukemia (ALL) approach with induction, consolidation, and maintenance therapy for a total of 24 months, disease-free survival rates higher than 90% have been reported for children with low-stage lymphoblastic lymphoma (cited Termuhlen et al. as reference 10).
Added Oschlies et al., Lorsbach et al., Agrawal et al., and Louissaint et al. as references 16, 17, 18, and 19, respectively.
Added text to state that subcutaneous mature T-cell lymphomas are very rare in children; an oral retinoid (bexarotene) has been reported to be active against subcutaneous T-cell lymphomas in children (cited Mehta et al. as reference 20).
Revised Table 4 to include the COG-A5971, modified Children's Cancer Group–Berlin-Frankfurt-Munster ALL therapy, as a treatment option for lymphoblastic lymphoma.
Added Pillon et al. as reference 6.
Added Godot et al. as reference 8.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.